Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 14/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26772301 | 0.89 | IL1B (0.59) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL26772113 | 0.86 | IL1B (0.73) | IL1BNLRP3CHEK2 | |
| SCHEMBL26117680 | 0.82 | NLRP3 (0.52) | IL1BNLRP3CHEK2 | |
| SCHEMBL26117671 | 0.82 | NLRP3 (0.52) | IL1BNLRP3CHEK2 | |
| SCHEMBL26772182 | 0.82 | NLRP3 (0.61) | IL1BNLRP3KCNH2TNF | |
| SCHEMBL31359831 | 0.77 | NLRP3 (0.45) | IL1BNLRP3CHEK2 | |
| SCHEMBL26112514 | 0.77 | NLRP3 (0.45) | IL1BNLRP3CHEK2 | |
| SCHEMBL26112505 | 0.77 | NLRP3 (0.45) | IL1BNLRP3CHEK2 | |
| SCHEMBL26772275 | 0.76 | IL1B (0.74) | IL1BNLRP3 | |
| SCHEMBL26772270 | 0.76 | IL1B (0.76) | IL1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. | 2023-11-16 | — | — | US | disclosed |
| WO-2023220408-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | Neumora Therapeutics, Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365534-A1 | MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS | NLRP3, NLRP1, PYCARD | IL1B 9/4885NLRP3 1/4885KCNH2 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.